Table 2.
Multivariable logistic regression analyses assessing the association of SII with adverse surgical features in 214 radio-recurrent PCa treated with SRP
| Characteristic | N | pT ≥ 3 | Lymph node metastasis (pN ≥ 1) | Non-organ confined disease | Adverse pathology | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | OR | 95% CI | p-value | OR | 95% CI | p-value | ||
| SII (high vs. low) | 214 | 1.74 | 0.94–3.22 | 0.08 | 3.32 | 1.45–7.90 | 0.005 | 2.55 | 1.33–4.97 | 0.005 | 2.20 | 1.15–4.33 | 0.019 |
| Age | 214 | 1.03 | 0.98–1.08 | 0.21 | 0.99 | 0.92–1.06 | 0.72 | 1.04 | 0.99–1.10 | 0.09 | 1.04 | 0.99–1.09 | 0.17 |
| Biopsy GS | 214 | 1.26 | 0.94–1.69 | 0.12 | 2.38 | 1.65–3.54 | < 0.001 | 1.53 | 1.12–2.13 | 0.010 | 1.66 | 1.20–2.35 | 0.003 |
| PSA | 206 | 1.10 | 1.01–1.19 | 0.02 | 1.11 | 1.02–1.22 | 0.022 | 1.18 | 1.08–1.32 | 0.001 | 1.17 | 1.06–1.31 | 0.002 |
| cT | |||||||||||||
| T1 | 99 | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | ||||
| T2 | 84 | 1.52 | 0.82–2.83 | 0.19 | 0.57 | 0.22–1.43 | 0.24 | 1.58 | 0.83–3.04 | 0.17 | 1.58 | 0.83–3.05 | 0.16 |
| T3 | 30 | 2.72 | 0.99–7.46 | 0.05 | 0.75 | 0.20–2.44 | 0.64 | 2.31 | 0.81–7.31 | 0.13 | 3.67 | 1.18–14.0 | 0.035 |
|
AUC (full model): 0.692 AUC (model without SII): 0.690 p = 0.914 |
AUC (full model): 0.821 AUC (model without SII): 0.767 p = 0.055 |
AUC (full model): 0.748 AUC (model without SII): 0.736 p = 0.540 |
AUC (full model): 0.753 AUC (model without SII): 0.746 p = 0.664 |
||||||||||
Non-organ confined diseases (pT ≥ 3 and/or pN ≥ 1); Adverse pathology (pT ≥ 3 and/or pN ≥ 1 and/or GS ≥ 8 and/or PSM)
CI confidence interval; DRE digital rectal examination; GS Gleason Score; OR odds ratio; PSA prostate-specific antigen; SRP salvage radical prostatectomy; SII Systemic Immune-inflammation Index